{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:11:15Z","timestamp":1788873075113,"version":"build-2803163510"},"reference-count":70,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ekir.2025.06.054","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T02:56:22Z","timestamp":1751684182000},"page":"2953-2966","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cardiovascular Complications in ADPKD"],"prefix":"10.1016","volume":"10","author":[{"given":"Niloufar","family":"Ebrahimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasar","family":"Caliskan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranav S.","family":"Garimella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol","family":"Carriazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouad T.","family":"Chebib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giv Heidari","family":"Bateni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neera K.","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjay","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Abdipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayna","family":"Norouzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2025.06.054_bib1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1053\/j.akdh.2023.06.002","article-title":"Assessing the risk of progression to kidney failure in patients with autosomal dominant polycystic kidney disease","volume":"30","author":"Lanktree","year":"2023","journal-title":"Adv Kidney Dis Health"},{"key":"10.1016\/j.ekir.2025.06.054_bib2","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2025.2492374","article-title":"Autosomal dominant polycystic kidney disease: an overview of recent genetic and clinical advances","volume":"47","author":"Borghol","year":"2025","journal-title":"Ren Fail"},{"key":"10.1016\/j.ekir.2025.06.054_bib3","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.kint.2024.07.010","article-title":"KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary","volume":"107","author":"Torres","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.06.054_bib4","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.06.054_bib5","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/j.ekir.2022.06.006","article-title":"Cardiovascular outcomes in kidney transplant recipients with ADPKD","volume":"7","author":"Chedid","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.06.054_bib6","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.ekir.2017.05.014","article-title":"Autosomal dominant polycystic kidney patients may be predisposed to various cardiomyopathies","volume":"2","author":"Chebib","year":"2017","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.06.054_bib7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.yjmcc.2013.01.015","article-title":"Polycystin-2 mutations lead to impaired calcium cycling in the heart and predispose to dilated cardiomyopathy","volume":"58","author":"Paavola","year":"2013","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.ekir.2025.06.054_bib8","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.ekir.2023.07.017","article-title":"Cardiovascular manifestations and management in ADPKD","volume":"8","author":"Sagar","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.06.054_bib9","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.06.054_bib10","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1523-1755.2003.00185.x","article-title":"Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort","volume":"64","author":"Chapman","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.06.054_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.693130","article-title":"Insights into the molecular mechanisms of polycystic kidney diseases","volume":"12","author":"Vasileva","year":"2021","journal-title":"Front Physiol"},{"key":"10.1016\/j.ekir.2025.06.054_bib12","doi-asserted-by":"crossref","first-page":"7175","DOI":"10.3390\/app13127175","article-title":"Assessment of cardiovascular disease in autosomal dominant polycystic kidney disease","volume":"13","author":"Gigante","year":"2023","journal-title":"Appl Sci"},{"key":"10.1016\/j.ekir.2025.06.054_bib13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000525944","article-title":"The pathophysiology of left ventricular hypertrophy, beyond hypertension, in Autosomal Dominant Polycystic Kidney Disease","volume":"148","author":"Oto","year":"2024","journal-title":"Nephron"},{"key":"10.1016\/j.ekir.2025.06.054_bib14","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.06.054_bib15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/j.ajkd.2024.06.020","article-title":"Effect of dual RAAS blockade and intensive BP lowering on risk of end-stage kidney disease and death in autosomal dominant polycystic kidney disease: long-term follow-up of the HALT-PKD trials","volume":"85","author":"Ku","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.06.054_bib16","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A Randomized Trial of Intensive versus Standard Blood-Pressure Control","volume":"373","author":"Group","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.06.054_bib17","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1681\/ASN.2018060590","article-title":"A practical guide for treatment of rapidly progressive ADPKD with tolvaptan","volume":"29","author":"Chebib","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.06.054_bib18","doi-asserted-by":"crossref","first-page":"42515","DOI":"10.18632\/oncotarget.6452","article-title":"Antihypertensive treatments in adult autosomal dominant polycystic kidney disease: network meta-analysis of the randomized controlled trials","volume":"6","author":"Xue","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ekir.2025.06.054_bib19","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016804","article-title":"Nonpharmacologic interventions for reducing blood pressure in adults with Prehypertension to established hypertension","volume":"9","author":"Fu","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ekir.2025.06.054_bib20","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.kint.2020.04.053","article-title":"Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease","volume":"98","author":"Kramers","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.06.054_bib21","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.ekir.2025.03.020","article-title":"Kidney function trajectories with tolvaptan in ADPKD patients with CKD-G5","volume":"10","author":"Sekine","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.06.054_bib22","doi-asserted-by":"crossref","first-page":"126","DOI":"10.34067\/KID.0000000000000066","article-title":"Defining cardiac dysfunction in ADPKD","volume":"4","author":"Kuo","year":"2023","journal-title":"Kidney360"},{"key":"10.1016\/j.ekir.2025.06.054_bib23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1525-139X.2011.01011.x","article-title":"Diastolic heart failure in dialysis patients: mechanisms, diagnostic approach, and treatment","volume":"25","author":"Pecoits-Filho","year":"2012","journal-title":"Semin Dial"},{"key":"10.1016\/j.ekir.2025.06.054_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ceca.2023.102733","article-title":"Calcium signaling in polycystic kidney disease- cell death and survival","volume":"112","author":"Marquez-Nogueras","year":"2023","journal-title":"Cell Calcium"},{"key":"10.1016\/j.ekir.2025.06.054_bib25","doi-asserted-by":"crossref","first-page":"H1021","DOI":"10.1152\/ajpheart.00302.2020","article-title":"Deletion of cardiac polycystin 2\/PC2 results in increased SR calcium release and blunted adrenergic reserve","volume":"319","author":"DiNello","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ekir.2025.06.054_bib26","doi-asserted-by":"crossref","first-page":"16604","DOI":"10.1073\/pnas.1415933111","article-title":"Decreased polycystin 2 expression alters calcium-contraction coupling and changes \u03b2-adrenergic signaling pathways","volume":"111","author":"Kuo","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ekir.2025.06.054_bib27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ijcard.2018.10.063","article-title":"Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: a cross-sectional and longitudinal substudy of the ALADIN trial","volume":"275","author":"Spinelli","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ekir.2025.06.054_bib28","doi-asserted-by":"crossref","first-page":"150","DOI":"10.34067\/KID.0002942022","article-title":"Cardiac manifestations in patients with autosomal dominant polycystic kidney disease (ADPKD): a single-center study","volume":"4","author":"Arjune","year":"2023","journal-title":"Kidney360"},{"key":"10.1016\/j.ekir.2025.06.054_bib29","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3949\/ccjm.84a.16107","article-title":"Autosomal dominant polycystic kidney disease and the heart and brain","volume":"84","author":"Krishnappa","year":"2017","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.ekir.2025.06.054_bib30","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1159\/000492244","article-title":"The association of fibroblast growth factor 23 with arterial stiffness and atherosclerosis in patients with autosomal dominant polycystic kidney disease","volume":"43","author":"Coban","year":"2018","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.ekir.2025.06.054_bib31","first-page":"275","article-title":"FGF23 and mineral metabolism, implications in CKD-MBD","volume":"32","author":"Rodriguez","year":"2012","journal-title":"Nefrologia"},{"key":"10.1016\/j.ekir.2025.06.054_bib32","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1007\/s00467-012-2384-5","article-title":"From bone abnormalities to mineral metabolism dysregulation in autosomal dominant polycystic kidney disease","volume":"28","author":"Mekahli","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2025.06.054_bib33","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI114844","article-title":"An insertion\/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels","volume":"86","author":"Rigat","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ekir.2025.06.054_bib34","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.kint.2016.04.028","article-title":"Cardiac dysfunction in Pkd1-deficient mice with phenotype rescue by galectin-3 knockout","volume":"90","author":"Balbo","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.06.054_bib35","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-019-1555-z","article-title":"Left ventricular hypertrophy in a contemporary cohort of autosomal dominant polycystic kidney disease patients","volume":"20","author":"Chen","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2025.06.054_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11205982","article-title":"Echocardiographic abnormalities in autosomal dominant polycystic kidney disease (ADPKD) patients","volume":"11","author":"Pfeferman","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ekir.2025.06.054_bib37","article-title":"Mitral valve prolapse and its motley crew-syndromic prevalence, pathophysiology, and progression of a common heart condition","volume":"10","author":"Nieman","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ekir.2025.06.054_bib38","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00467-022-05500-w","article-title":"Prevalence of cardiac valvar abnormalities in children and young people with autosomal dominant polycystic kidney disease","volume":"38","author":"Savis","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2025.06.054_bib39","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1053\/ajkd.2001.29216","article-title":"Mitral valve prolapse and mitral regurgitation are common in patients with polycystic kidney disease type 1","volume":"38","author":"Lumiaho","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.06.054_bib40","first-page":"185","article-title":"Immunolocalization of polycystin in human tissues and cultured cells","volume":"108","author":"Griffin","year":"1996","journal-title":"Proc Assoc Am Physicians"},{"key":"10.1016\/j.ekir.2025.06.054_bib41","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/ndt\/gft437","article-title":"Extra-renal manifestations of autosomal dominant polycystic kidney disease (ADPKD): considerations for routine screening and management","volume":"29","author":"Luciano","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.06.054_bib42","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.amjcard.2018.10.030","article-title":"Risk of ascending aortic aneurysm in patients with autosomal dominant polycystic kidney disease","volume":"123","author":"Bouleti","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ekir.2025.06.054_bib43","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1038\/s41598-020-58441-5","article-title":"Prognosis of vascular access in haemodialysis patients with autosomal dominant polycystic kidney disease","volume":"10","author":"Lee","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2025.06.054_bib44","doi-asserted-by":"crossref","first-page":"57594","DOI":"10.18632\/oncotarget.16338","article-title":"Risk of aortic aneurysm and dissection in patients with autosomal-dominant polycystic kidney disease: a nationwide population-based cohort study","volume":"8","author":"Sung","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ekir.2025.06.054_bib45","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.ekir.2024.02.007","article-title":"Aortic dilatation in children and young people with ADPKD","volume":"9","author":"Savis","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.06.054_bib46","doi-asserted-by":"crossref","DOI":"10.34067\/KID.0000000000000322","article-title":"All patients with ADPKD should undergo screening for intracranial aneurysms: CON","volume":"5","author":"Chebib","year":"2024","journal-title":"Kidney360"},{"key":"10.1016\/j.ekir.2025.06.054_bib47","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(03)13773-7","article-title":"Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype","volume":"361","author":"Rossetti","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2025.06.054_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.mayocp.2025.02.003","article-title":"Intracranial aneurysms in autosomal dominant polycystic kidney disease: a practical approach to screening and management","volume":"100","author":"Borghol","year":"2025","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ekir.2025.06.054_bib49","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000513709","article-title":"Clinical factors associated with the risk of intracranial aneurysm rupture in autosomal dominant polycystic kidney disease","volume":"50","author":"Lee","year":"2021","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.ekir.2025.06.054_bib50","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2215\/CJN.14691218","article-title":"Presymptomatic screening for intracranial aneurysms in patients with autosomal dominant polycystic kidney disease","volume":"14","author":"Sanchis","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.06.054_bib51","article-title":"Pericardial effusion on MRI in autosomal dominant polycystic kidney disease","volume":"11","author":"Liu","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ekir.2025.06.054_bib52","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1242\/dmm.003194","article-title":"The ADPKD genes pkd1a\/b and pkd2 regulate extracellular matrix formation","volume":"3","author":"Mangos","year":"2010","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.ekir.2025.06.054_bib53","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/ckj\/sfad181","article-title":"Prevalence of pericardial effusion in autosomal dominant polycystic kidney disease","volume":"16","author":"Jost","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.06.054_bib54","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1159\/000343281","article-title":"Prevalence of cardiovascular events in patients with autosomal dominant polycystic kidney disease","volume":"36","author":"Helal","year":"2012","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2025.06.054_bib55","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3109\/0886022X.2016.1144209","article-title":"Autosomal dominant polycystic kidney disease and coronary artery dissection or aneurysm: a systematic review","volume":"38","author":"Neves","year":"2016","journal-title":"Ren Fail"},{"key":"10.1016\/j.ekir.2025.06.054_bib56","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ekir.2019.12.007","article-title":"Polycystins, ADPKD, and cardiovascular disease","volume":"5","author":"Kuo","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.06.054_bib57","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/ki.1992.195","article-title":"Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease","volume":"41","author":"Gabow","year":"1992","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.06.054_bib58","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/ki.1988.233","article-title":"Hypertension in autosomal dominant polycystic kidney disease","volume":"34","author":"Bell","year":"1988","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.06.054_bib59","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/00007890-201407151-01729","article-title":"Prevalence of left ventricular hypertrophy in kidney transplant recipients with autosomal dominant polycystic kidney disease","volume":"98","author":"Jankowska","year":"2014","journal-title":"Transplantation"},{"issue":"suppl 1","key":"10.1016\/j.ekir.2025.06.054_bib60","article-title":"P5245Autosomal polycystic kidney disease carries an increased risk of aortic root aneurysm","volume":"38","author":"Bouleti","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2025.06.054_bib61","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12882-021-02313-1","article-title":"Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease","volume":"22","author":"Gorriz","year":"2021","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2025.06.054_bib62","doi-asserted-by":"crossref","first-page":"19365","DOI":"10.18632\/oncotarget.14269","article-title":"An association between autosomal-dominant polycystic kidney disease and the risk of acute myocardial infarction in Asian population-results of a nationwide study","volume":"8","author":"Sung","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ekir.2025.06.054_bib63","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1146\/annurev-med-050913-022838","article-title":"Vasopressin receptor antagonists, heart failure, and polycystic kidney disease","volume":"66","author":"Torres","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.ekir.2025.06.054_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1367442","article-title":"The role of tolvaptan add-on therapy in patients with acute heart failure: a systematic review and network meta-analysis","volume":"11","author":"Pratama","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ekir.2025.06.054_bib65","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2174\/1570161118999200918094809","article-title":"Cardiovascular risk and quality of life in autosomal dominant polycystic kidney disease patients on therapy with tolvaptan: A pilot study","volume":"19","author":"Lai","year":"2021","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.ekir.2025.06.054_bib66","first-page":"167","article-title":"Evaluation of the renal and cardiovascular effects of long-term tolvaptan treatment in autosomal dominant polycystic kidney disease","volume":"14","author":"Demiray","year":"2024","journal-title":"Cardiorenal Med"},{"key":"10.1016\/j.ekir.2025.06.054_bib67","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfaf061","article-title":"SGLT2 inhibition for patients with ADPKD - closing the evidence gap","author":"Muller","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.06.054_bib68","doi-asserted-by":"crossref","DOI":"10.2215\/CJN.0000000725","article-title":"Sodium-glucose Cotransporter-2 inhibitor therapy and longitudinal changes in kidney function among veterans with autosomal dominant polycystic kidney disease","author":"Eswarappa","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.06.054_bib69","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/ckj\/sfac029","article-title":"Sodium-glucose cotransporter inhibition in polycystic kidney disease: fact or fiction","volume":"15","author":"Afsar","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.06.054_bib70","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1053\/j.ajkd.2018.12.037","article-title":"Mineralocorticoid antagonism and vascular function in early autosomal dominant polycystic kidney disease: a randomized controlled trial","volume":"74","author":"Nowak","year":"2019","journal-title":"Am J Kidney Dis"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925004279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925004279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T17:40:47Z","timestamp":1758130847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024925004279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":70,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2468024925004279"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2025.06.054","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Complications in ADPKD","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.06.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}